Anbio Biotechnology

NNNNHealthcare·Medical Instruments & Supplies·Germany·Small·NASD·Nov 11 • 3:59 PM ET

4.05+0.25 (6.58%)

2026-11-12 07:50 CET

Market cap

177.76 USD m

Revenue, TTM

9.74 USD m

Net income, TTM

7.19 USD m

Free cash flow, TTM

- USD m

EPS diluted, TTM

0.16

P/E

24.74

Compare

Price

NNNN against its 20, 50 and 200-day averages

2050200

Patternshover a marker to name it

90.9% under the 52-week high of 44.73 on 5 Dec 2025. 52-week low 3.09 on 15 Oct 2026. Last 15 sessions, 32.9% high to low

Volume 0.16× normal · the line is the 50-bar volume average

Profile

NNNN

52-week range, 2% of the way up

3.0944.73

Anbio Biotechnology is a medical device company. It is focused on developing and manufacturing a range of in-vitro diagnostic (IVD) products. The company was founded on July 27, 2021 and is headquartered in Frankfurt, Germany.

Employees	27
IPO	Feb 19, 2025
Beta	5.56
ATR, 14d	0.48
Rel volume	0.16
Short float	0.08%
Insider own	9.57%
Inst own	0.15%

Snapshot

6 groups

Valuation

Index	-
Market Cap	582.76M
Enterprise Value	568.78M
Income	7.19M
Sales	9.74M
Book/sh	0.81
Cash/sh	0.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	27
IPO	Feb 19, 2025

Ratios

P/E	24.74
Forward P/E	-
PEG	-
P/S	59.83
P/B	5.02
P/C	41.69
P/FCF	-
EV/EBITDA	87.78
EV/Sales	58.40
Quick Ratio	344.31
Current Ratio	344.31
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

Earnings

EPS (ttm)	0.16
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-12.86% 23.44%
Sales past 3/5Y	-26.67% 16.85%
EPS Y/Y TTM	170.13%
Sales Y/Y TTM	10.10%
EPS Q/Q	321.09%
Sales Q/Q	87.39%
Earnings	-
EPS/Sales Surpr.	- -

Ownership

Insider Own	9.57%
Insider Trans	0.00%
Inst Own	0.15%
Inst Trans	2.54%
ROA	26.08%
ROE	27.01%
ROIC	20.29%
Gross Margin	87.06%
Oper. Margin	66.47%
Profit Margin	73.75%
SMA20	10.68%
SMA50	-16.78%
SMA200	-75.17%
Trades	-

Technical

Shs Outstand	43.89M
Shs Float	39.69M
Short Float	0.08%
Short Ratio	0.22
Short Interest	0.03M
52W High	44.73 -90.95%
52W Low	3.09 31.07%
Volatility	13.96% 12.71%
ATR (14)	0.48
RSI (14)	47.88
Beta	5.56
Rel Volume	0.16
Avg Volume	149.14K
Volume	23,509

Performance

Perf Week	10.05%
Perf Month	-4.93%
Perf Quarter	-60.53%
Perf Half Y	-83.95%
Perf YTD	-86.53%
Perf Year	-82.49%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	3.80
Price	4.05
Change %	6.58%

Peers

Mkt cap

Ticker	Company	Mkt cap
OSUR	Orasure Technologies Inc	245.81M
QDEL	QuidelOrtho Corp	817.18M
BDX	Becton Dickinson & Co	58.43B
ABT	Abbott Laboratories	189.28B
BMRA	Biomerica Inc	6.95M
CODX	Co-Diagnostics Inc	2.64M
TRIB	Trinity Biotech Plc ADR	3.72M
DHR	Danaher Corp	165.55B
BIO	Bio-Rad Laboratories Inc	10.39B
DGX	Quest Diagnostics Inc	28.46B

Ticker

Company

Mkt cap

OSUR

Orasure Technologies Inc

245.81M

QDEL

QuidelOrtho Corp

817.18M

BDX

Becton Dickinson & Co

58.43B

ABT

Abbott Laboratories

189.28B

BMRA

Biomerica Inc

6.95M

CODX

Co-Diagnostics Inc

2.64M

TRIB

Trinity Biotech Plc ADR

3.72M

DHR

Danaher Corp

165.55B

BIO

Bio-Rad Laboratories Inc

10.39B

DGX

Quest Diagnostics Inc

28.46B

Held by

AUM

Ticker	Company	AUM
GWX	State Street SPDR S&P International Small Cap ETF	AUM: 906.57M

Ticker

Company

AUM

GWX

State Street SPDR S&P International Small Cap ETF

AUM: 906.57M

Key figures

Revenue, TTM	9.74
Net income, TTM	7.19
EPS diluted, TTM	0.16
EBIT, TTM	6.48
Free cash flow, TTM	-
Gross margin	87.06%
Operating margin	66.47%
Net margin	73.75%
Market cap	177.76
P/E	24.74
Sales Y/Y, TTM	10.10%

USD millions. TTM from the statement feed.

Quarterly earnings

actual against estimate

Period	Reported	EPS act	EPS est	EPS rep	Sales act	Sales est	Analysts
No quarterly earnings.

Period

Reported

EPS act

EPS est

EPS rep

Sales act

Sales est

Analysts

No quarterly earnings.

Annual earnings

Period	EPS act	EPS est	EPS rep	Sales act	Sales est
No annual earnings.

Period

EPS act

EPS est

EPS rep

Sales act

Sales est

No annual earnings.

Estimate revisions

last 14 periods

Period	Type	Date	Estimates	Up	Down	Mean	Low	High
No estimate revisions.

Period

Type

Date

Estimates

Down

Mean

Low

High

No estimate revisions.

Estimate history

Period	2021	2022	2023	2024	2025
EPS, annual	0.071	0.249	0.058	0.061	0.165
EPS, quarterly
Period
Sales, annual	5.234	24.745	7.256	8.854	9.759
Period	2021	2022	2023	2024	2025
Sales, quarterly
Period
Shares, annual	42.291	42.291	42.291	42.291	43.891
Period	2021	2022	2023	2024	2025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY
Total Revenue	9.74	9.76	8.85	7.26	24.74	5.23
Cost of Goods Sold Incl. D&A	1.26	1.25	2.49	3.62	11.54	2.23
Gross Profit	8.48	8.51	6.37	3.63	13.20	3.00
Selling, General and Administrative Excl. Other	2.01	2.00	4.21	1.51	2.49	0.10
Research and Development	0.23	0.23	0.49	0.15	0.21	0.00
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	6.48	6.51	2.16	2.12	10.72	2.90
Interest Expense	0.00	0.00	0.00	0.00	0.01	0.00
Unusual Expense	0.18	0.00	0.00	0.00	0.00	0.00
Net Income Before Taxes	7.19	7.23	2.57	2.44	10.52	3.00
Income Taxes	0.00	0.00	0.00	0.00	0.00	0.00
Consolidated Net Income	7.19	7.23	2.57	2.44	10.52	3.00
Net Income From Continuing Operations	7.19	7.23	2.57	2.44	10.52	3.00
Net Income	7.19	7.23	2.57	2.44	10.52	3.00
EPS (Recurring)	0.17	0.16	0.06	0.06	0.25	0.07
EPS (Basic, Before Extraordinaries)	0.16	0.16	0.06	0.06	0.25	0.07
EPS (Diluted)	0.16	0.16	0.06	0.06	0.25	0.07
EBITDA	6.48	6.51	2.16	2.13	10.72	2.90
Non-Operating Income (Expense)	0.70	0.72	0.41	0.32	-0.19	0.09
Other After Tax Adjustments	0.00	0.00	0.00	0.00	0.00	0.00
Price To Earnings Ratio	24.74	24.74	474.53	-	-	-
Price To Sales Ratio	135.44	135.25	-	-	-	-
Gross Margin	87.06	87.24	71.90	50.07	53.36	57.40
Operating Margin	66.47	66.70	24.38	29.22	43.30	55.46
Net Margin	73.75	74.06	28.99	33.58	42.52	57.26
Shares Outstanding	43.89	43.89	42.29	42.29	42.29	42.29
Market Capitalization	177.76	177.76	1,316.30	-	-	-

Income statement, quarterly

Currency USD, millions
Metric	2025S2	2025S1	2024S2	2024S1	2023S2	2023S1	2022S2	2022S1
Total Revenue	4.74	5.01	2.53	6.32	3.95	3.31	5.78	19.49
Cost of Goods Sold Incl. D&A	0.88	0.38	0.39	2.10	2.26	1.36	3.35	8.38
Gross Profit	3.86	4.62	2.14	4.23	1.69	1.94	2.43	11.11
Selling, General and Administrative Excl. Other	1.06	0.95	3.87	0.34	1.11	0.41	2.39	0.01
Research and Development	0.08	0.14	0.35	0.14	0.15	-	0.20	-
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	2.80	3.68	-1.74	3.89	0.58	1.54	0.03	11.10
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Unusual Expense	0.00	0.18	0.00	0.00	0.00	0.00	0.00	0.00
Net Income Before Taxes	3.04	4.15	-1.32	3.89	0.79	1.64	-0.00	10.94
Income Taxes	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Consolidated Net Income	3.04	4.15	-1.32	3.89	0.79	1.64	-0.00	10.94
Net Income From Continuing Operations	3.04	4.15	-1.32	3.89	0.79	1.64	-0.00	10.94
Net Income	3.04	4.15	-1.32	3.89	0.79	1.64	-0.00	10.94
EPS (Recurring)	0.07	0.10	-0.03	0.09	0.02	0.04	-0.00	0.26
EPS (Basic, Before Extraordinaries)	0.07	0.09	-0.03	0.09	0.02	0.04	0.00	0.26
EPS (Diluted)	0.07	0.09	-0.03	0.09	0.02	0.04	0.00	0.26
EBITDA	2.80	3.68	-1.74	3.89	0.59	1.55	0.04	11.10
Non-Operating Income (Expense)	0.05	0.65	0.41	-0.00	0.21	0.11	-0.03	-0.16
Price To Earnings Ratio	24.74	522.44	515.02	-	-	-	-	-
Price To Sales Ratio	135.44	184.41	-	-	-	-	-	-
Gross Margin	81.49	92.32	84.55	66.85	42.82	58.73	41.96	57.01
Operating Margin	59.09	73.45	-68.64	61.51	14.78	46.45	0.57	56.96
Net Margin	64.14	82.84	-52.40	61.48	20.07	49.70	-0.01	56.12
Shares Outstanding	43.89	43.89	42.29	42.29	42.29	42.29	42.29	42.29
Market Capitalization	177.76	1,389.60	1,369.84	-	-	-	-	-

Balance sheet, annual

Currency USD, millions
Metric	2025FY	2024FY	2023FY	2022FY	2021FY
Cash & Short Term Investments	13.98	12.18	10.70	9.25	4.76
Short Term Receivables	4.29	1.10	2.08	0.00	0.82
Inventories	0.00	0.00	0.00	0.38	0.00
Other Current Assets	17.25	5.91	4.61	5.25	0.02
Total Current Assets	35.52	19.19	17.40	14.88	5.59
Net Property, Plant & Equipment	0.00	0.00	0.00	0.01	0.00
Total Investments and Advances	0.00	0.00	0.00	0.00	0.00
Long-Term Note Receivable	-	0.00	0.02	-	-
Intangible Assets	0.00	0.00	0.00	0.00	0.00
Other Assets	0.00	0.40	0.05	0.00	0.00
Total Assets	35.52	19.59	17.47	14.90	5.59
Short Term Debt Incl. Current Port. of LT Debt	0.00	0.00	0.00	0.00	0.00
Accounts Payable	0.00	1.68	0.91	1.50	2.15
Other Current Liabilities	0.10	0.11	0.18	0.00	0.56
Total Current Liabilities	0.10	1.79	1.10	1.51	2.71
Long Term Debt	0.00	0.00	0.00	0.00	0.00
Provision for Risks Charges	0.00	0.00	0.00	0.00	0.00
Other Liabilities	0.00	0.00	0.00	0.00	0.00
Total Liabilities	0.10	1.79	1.10	1.51	2.71
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.00
Common Equity	35.42	17.80	16.37	13.39	2.88
Total Shareholders Equity	35.42	17.80	16.37	13.39	2.88
Accumulated Minority Interest	0.00	0.00	0.00	0.00	0.00
Total Equity	35.42	17.80	16.37	13.39	2.88
Total Liabilities & Stockholders Equity	35.52	19.59	17.47	14.90	5.59
Book Value Per Share	0.81	0.42	0.39	0.32	0.07
Tangible Book Value Per Share	0.81	0.42	0.39	0.32	0.07
Full-Time Employees	27	27	27	27	27
Price to Book Ratio	5.02	40.70	-	-	-
Return on Assets	26.23	13.85	15.06	102.71	-
Return on Equity	27.16	15.02	16.37	129.30	-
Return on Invested Capital	20.41	14.42	14.88	78.57	103.94
Quick Ratio	344.31	10.71	15.86	9.63	2.07
Current Ratio	344.31	10.71	15.86	9.88	2.07

Cash flow, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY
Net Income	-	7.23	2.57	2.44	10.52	3.00
Depreciation	-	0.00	0.00	0.01	0.01	0.00
Deferred Taxes & Investment Tax Credit	-	0.00	0.00	0.00	0.00	0.00
Other Funds (Non Cash)	-	0.08	-0.36	-0.18	0.00	0.00
Funds from Operations	-	7.30	2.20	2.27	10.53	3.00
Extraordinary Item	-	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	-	-14.91	0.05	-1.30	-5.81	1.94
Cash from Operating Activities	-	-7.61	2.25	0.97	4.72	4.94
Capital Expenditures	-	0.00	0.00	0.00	0.00	0.00
Net Assets From Acquisitions	-	0.00	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	-	0.00	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	-	-4.74	0.36	1.87	-1.65	0.00
Purchase of Investments	-	-21.92	-38.36	-20.05	-1.65	0.00
Sale Or Maturity of Investments	-	17.17	38.73	21.92	0.00	0.00
Other Uses	-	0.00	0.00	0.00	0.00	0.00
Other Sources	-	0.00	0.00	0.00	0.00	0.00
Cash from Investing Activities	-	-4.74	0.36	1.87	-1.65	0.00
Cash Dividends Paid	-	0.00	0.00	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	-	0.00	0.00	0.00	0.00	0.00
Change in Capital Stock	-	7.84	-0.37	-0.05	0.00	0.00
Repurchase of Common Pref Stock	-	0.00	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	-	7.84	-0.37	-0.05	0.00	0.00
Proceedsfrom Stock Options	-	7.84	-0.37	-0.05	0.00	0.00
Issuance or Reduction of Debt, Net	-	0.00	0.00	0.00	0.00	0.00
Change in Long Term Debt	-	0.00	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	-	0.00	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	-	0.00	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	-	0.00	0.00	0.00	0.00	0.00
Other Financing Activities Uses	-	0.00	0.00	0.00	0.00	0.00
Cash from Financing Activities	-	7.84	-0.37	-0.05	0.00	0.00
Net Change in Cash	-	-4.51	2.24	2.80	3.07	4.94
Free Cash Flow	-	-7.61	2.25	0.97	4.72	4.94

Balance sheet, quarterly

Currency USD, millions
Metric	2025S2	2025S1	2024S2	2024S1	2023S2	2023S1
Cash & Short Term Investments	13.98	15.76	12.18	11.05	10.70	11.52
Short Term Receivables	4.29	4.36	1.10	4.95	2.08	0.00
Inventories	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	17.25	12.37	5.91	4.12	4.61	5.00
Total Current Assets	35.52	32.49	19.19	20.11	17.40	16.53
Net Property, Plant & Equipment	0.00	0.00	0.00	0.00	0.00	0.00
Total Investments and Advances	0.00	0.00	0.00	0.00	0.00	0.00
Intangible Assets	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	0.00	0.00	0.40	0.17	0.05	0.28
Total Assets	35.52	32.49	19.59	20.30	17.47	16.83
Short Term Debt Incl. Current Port. of LT Debt	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable	0.00	0.07	1.68	0.51	0.91	1.43
Other Current Liabilities	0.10	0.08	0.11	0.05	0.18	0.04
Total Current Liabilities	0.10	0.15	1.79	0.57	1.10	1.46
Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	0.10	0.15	1.79	0.57	1.10	1.46
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.00	0.00
Common Equity	35.42	32.34	17.80	19.74	16.37	15.37
Total Shareholders Equity	35.42	32.34	17.80	19.74	16.37	15.37
Accumulated Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity	35.42	32.34	17.80	19.74	16.37	15.37
Total Liabilities & Stockholders Equity	35.52	32.49	19.59	20.30	17.47	16.83
Book Value Per Share	0.81	0.74	0.42	0.47	0.39	0.36
Tangible Book Value Per Share	0.81	0.74	0.42	0.47	0.39	0.36
Price to Book Ratio	5.02	75.21	74.14	-	-	-
Return on Assets	26.08	10.70	13.83	25.21	15.06	-
Return on Equity	27.01	10.84	15.00	26.67	16.37	-
Return on Invested Capital	8.58	12.83	-7.44	19.70	4.84	10.69
Quick Ratio	344.31	211.10	10.71	35.56	15.86	11.29
Current Ratio	344.31	211.10	10.71	35.56	15.86	11.29

Cash flow, quarterly

Currency USD, millions
Metric	2025S2	2025S1	2024S2	2024S1	2023S2	2023S1
Net Income	-	-	-1.32	3.89	0.79	1.64
Depreciation	-	-	0.00	0.00	0.00	0.01
Other Funds (Non Cash)	-	-	-0.22	-0.15	-0.18	0.00
Funds from Operations	-	-	-1.53	3.74	0.62	1.65
Extraordinary Item	-	-	0.00	0.00	0.00	0.00
Changes in Working Capital	-	-	3.14	-3.09	-1.97	0.67
Cash from Operating Activities	-	-	1.60	0.65	-1.35	2.32
Capital Expenditures	-	-	0.00	0.00	0.00	0.00
Net Assets From Acquisitions	-	-	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	-	-	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	-	-	0.22	0.15	0.18	1.69
Purchase of Investments	-	-	-11.36	-27.03	-20.06	0.00
Sale Or Maturity of Investments	-	-	11.58	27.18	20.24	1.69
Other Uses	-	-	0.00	0.00	0.00	0.00
Other Sources	-	-	0.00	0.00	0.00	0.00
Cash from Investing Activities	-	-	0.22	0.15	0.18	1.69
Cash Dividends Paid	-	-	0.00	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	-	-	0.00	0.00	0.00	0.00
Change in Capital Stock	-	-	-0.25	-0.12	0.23	-0.28
Repurchase of Common Pref Stock	-	-	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	-	-	-0.25	-0.12	0.23	-0.28
Proceedsfrom Stock Options	-	-	-0.25	-0.12	0.23	-0.28
Issuance or Reduction of Debt, Net	-	-	0.00	0.00	0.00	0.00
Change in Long Term Debt	-	-	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	-	-	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	-	-	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	-	-	0.00	0.00	0.00	0.00
Other Financing Activities Uses	-	-	0.00	0.00	0.00	0.00
Cash from Financing Activities	-	-	-0.25	-0.12	0.23	-0.28
Net Change in Cash	-	-	1.57	0.67	-0.94	3.74
Free Cash Flow	-	-	1.60	0.65	-1.35	2.32

Revenue breakdown

In Vitro & In Vivo Diagnostic Substances	2024: 8.19M 2025: 8.65M
Asia Pacific	2024: 509.17K 2025: 1.52M
European Union	2024: 5.62M 2025: 5.15M
North America	2024: 110.51K 2025: 296.20K
Other Regions	2024: 472.38K 2025: 1.41M
South America	2024: 1.48M 2025: 269.54K

Short interest

shares short against float, oldest to newest

Settlement	Of float	Shares short	Float	Avg volume
2026-10-30	0.08%	0.0M	39.7M	149.86K
2026-10-15	0.08%	0.0M	39.7M	146.24K
2026-09-30	0.14%	0.1M	39.7M	147.20K
2026-09-15	0.13%	0.1M	39.7M	123.94K
2026-08-31	0.15%	0.1M	39.7M	88.11K
2026-08-14	0.07%	0.0M	39.7M	42.45K
2026-07-31	0.12%	0.0M	39.7M	38.02K
2026-07-15	0.08%	0.0M	39.7M	35.81K
2026-06-30	0.22%	0.1M	39.7M	33.16K
2026-06-15	0.22%	0.1M	39.7M	27.27K
2026-05-29	0.22%	0.1M	39.7M	29.05K
2026-05-15	0.23%	0.1M	39.7M	34.24K
2026-04-30	0.11%	0.0M	39.7M	47.67K
2026-04-15	0.13%	0.1M	39.7M	55.68K
2026-03-31	0.08%	0.0M	39.7M	57.04K
2026-03-13	0.09%	0.0M	39.7M	59.12K
2026-02-27	0.12%	0.0M	39.7M	56.73K
2026-02-13	0.13%	0.1M	39.7M	50.52K
2026-01-30	0.19%	0.1M	39.7M	42.44K
2026-01-15	0.13%	0.1M	39.7M	34.03K

Option chain

expiry 2026-11-12

Type	Strike	Bid	Ask	Last	IV	Open int	Volume	Delta	Theta	Vega
No option chain for this symbol.

Type

Strike

Bid

Ask

Last

Open int

Volume

Delta

Theta

Vega

No option chain for this symbol.

Latest SEC filings

Filed	Form	Description	Period	Link
2026-07-09	F-3ASR	Automatic shelf registration statement of securities of well-known seasoned issuers		SEC
2026-06-12	3	Initial statement of beneficial ownership of securities	2026-03-18	SEC
2026-06-12	3	Initial statement of beneficial ownership of securities	2026-03-18	SEC
2026-05-19	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-05-19	SEC
2026-04-27	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-04-27	SEC
2026-04-09	20-F/A		2025-12-31	SEC
2026-04-08	3	Initial statement of beneficial ownership of securities	2026-03-18	SEC
2026-04-08	3	Initial statement of beneficial ownership of securities	2026-03-18	SEC
2026-04-08	3	Initial statement of beneficial ownership of securities	2026-03-18	SEC
2026-04-08	3	Initial statement of beneficial ownership of securities	2026-03-18	SEC
2026-04-08	3	Initial statement of beneficial ownership of securities	2026-03-18	SEC
2026-04-07	20-F	Registration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.	2025-12-31	SEC
2026-02-17	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-02-17	SEC
2026-01-26	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-01-26	SEC
2025-12-30	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2025-12-30	SEC
2025-11-13	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2025-11-12	SEC
2025-04-28	20-F	Registration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.	2024-12-31	SEC
2025-02-21	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2025-02-21	SEC
2025-02-19	424B4			SEC
2025-02-18	EFFECT	Effectiveness filing by commission order		SEC
2025-02-18	CERT			SEC
2025-02-14	CORRESP			SEC
2025-02-14	CORRESP			SEC
2025-02-14	8-A12B			SEC
2025-02-10	F-1/A			SEC
2025-01-24	F-1/A			SEC
2025-01-22	FWP	Filing under Securities Act Rule 163/433 of free writing prospectuses.		SEC
2025-01-10	F-1/A			SEC
2024-12-31	F-1	Registration statement for certain foreign private issuers		SEC
2024-12-11	DRSLTR	Correspondence Submission of a DRS filer. Correspondence is not publicly disseminated immediately. The SEC staff may publicly release all or portions of these documents.		SEC

Insider activity by month

Month	Bought	Buys	Sold	Sells
2026-11	0	0	0	0
2026-10	0	0	0	0
2026-09	0	0	0	0
2026-08	0	0	0	0
2026-07	0	0	0	0
2026-06	0	0	0	0
2026-05	0	0	0	0
2026-04	0	0	0	0
2026-03	0	0	0	0
2026-02	0	0	0	0
2026-01	0	0	0	0
2025-12	0	0	0	0
2025-11	0	0	0	0

Institutional holders

Manager	% owned
GEODE CAPITAL MANAGEMENT, LLC	0.05%
BANK OF AMERICA CORP /DE/	0.03%
BNP PARIBAS FINANCIAL MARKETS	0.03%
MARSHALL WACE, LLP	0.03%
MORGAN STANLEY	0.02%
UBS Group AG	0.00%
Larson Financial Group LLC	0.00%
OSAIC HOLDINGS, INC.	0.00%
JPMORGAN CHASE & CO	0.00%
EverSource Wealth Advisors, LLC	0.00%

Funds

Fund	% owned
Fidelity Nasdaq Composite Index Fund	0.05%
Small Cap Core Fund	0.02%

Fund

% owned

Fidelity Nasdaq Composite Index Fund

0.05%

Small Cap Core Fund

0.02%

OakChart. NNNN. Cached 15 minutes.

Some panels did not load: ratings, insider, news.